Abstract. Plumbagin, a naphthoquinone derived from the medicinal plant Plumbago zeylanica, has been shown to exert anti-cancer and anti-proliferative activities in vitro as well as in animal tumor models. However, the mechanism underlying its anti-tumor action still remains unclear. CRM1 is a nuclear export receptor involved in the active transport of tumor suppressors whose function is altered in cancer due to increased expression and overactive transport. We showed that CRM1 is a direct cellular target of plumbagin. The nuclei of cells incubated with plumbagin accumulated tumor-suppressor proteins and inhibited the interactions between CRM1 and these proteins. Particularly, we demonstrated that plumbagin could specifically react with the conserved Cys 528 of CRM1 but not with a Cys 528 mutant peptide through Mass spectrometric analysis. More importantly, cancer cells that are transfected with mutant CRM1 (C528S) are resistant to the inhibitory effects of plumbagin, demonstrating that the inhibition is through direct interaction with Cys 528 of CRM1. The inhibition of nuclear traffic by plumbagin may account for its therapeutic properties in cancer and inflammatory diseases. Our findings could contribute to the development of a new class of CRM1 inhibitors.
Introduction
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a natural bicyclic naphthoquinone present in plants of the Droseraceae, Plumbaginaceae, and Dioncophyllaceae families (1) . The roots of plumbaginaceae have been widely used as an antiatherogenic, neuroprotective, and hepatoprotective agent in Indian traditional medicine. The main constituent, plumbagin, is an active compound exhibiting various reported pharmacological and biological activities including anti-microbial (2), anti-inflammatory (3), and anti-tumor activities (4, 5) . The anticancer properties of plumbagin have been demonstrated through studies in tumor cells as well as in experimental animals.
Recent reports on plumbagin have focused mainly on its anti-tumor activity and the underlying mechanisms.
Animal and cell studies have demonstrated that plumbagin has anticancer, antiproliferative, chemopreventive, chemotherapeutic, and radiosensitizing properties (4, 6) . It has been shown that plumbagin induces reactive oxygen species (ROS) resulting in apoptosis and cell cycle arrest (7) . Plumbagin also was reported to inhibit tumor angiogenesis and tumor growth by interference with the VEGFR2-mediated Ras signaling pathway in endothelial cells (8) . More recently, mechanistic studies revealed that the anti-tumor activity of plumbagin mainly through suppressing the constitutive NF-kB signal pathway in various cancer cells (4, 9) . Unfortunately, its detailed biological mechanism of action is still in much debate and remains to be elucidated. A critical structure feature of plumbagin is the electrophilic a,b-unsaturated carbonyl group as a Michael acceptor moiety. This has raised the question about how the Michael acceptor unit of plumbagin directly interacts with its cellular targets and accompanying biological activities.
Protein transport between the nucleus and the cytoplasm is critical for cell maintenance, cell proliferation, and survival. The major nuclear exporter protein CRM1 (chromosome maintenance region 1), also known as exportin 1, is a key member of the importin b superfamily of nuclear transport receptors (10) . CRM1 export cargo proteins that contain specific leucine-rich nuclear export signal (NES) consensus sequences (11) . Overexpression of CRM1 is linked to inactivation of tumor suppressor proteins, pro-proliferation, and resistance to chemotherapy (12) . Importantly, CRM1 is involved in nuclear export of a number of tumor suppressor proteins including p53, p21 (13) , inhibitor of kB-a (IkB-a) (14) , c-ABL (15), FOXOs (16) , and nucleophosmin-1 (NPM1), etc. (17) . The nuclear retention of these proteins could induce cancer cell apoptosis or cell cycle arrest (14) . Consequently, CRM1 could be considered to be a promising therapeutic target for anticancer drug development. To date, the CRM1 inhibitors block the nuclear export by covalently binding with Cys 528 of CRM1 by a Michael-type addition reaction and abrogate the interaction between CRM1 and its cargo proteins. A wellknown CRM1-specific inhibitor, leptomycin B (LMB), could covalently bind with Cys 528 through the unsaturated carbonyl group on the lactone ring (18) . The common structure feature of existing nuclear export inhibitors is the Michael acceptor unit as the thiol-reactive warhead.
In this report, for the first time, we demonstrated that CRM1 is a direct cellular target of plumbagin. Plumbagin covalently and selectively binds the sulfhydryl group of Cys 528 of CRM1 via its a,b-unsaturated carbonyl moiety through a Michael addition manner. Furthermore, our results are consistent with the pharmacological relevance of plumbagin and could explain its cell growth modulatory and anticarcinogenic effects previously reported. Our findings proposed a new type of CRM1 inhibitor and provided a natural product scaffold for the development of novel therapeutic agents.
Materials and Methods

Cell culture, antibodies, and reagents
The HeLa, MCF-7, and A172 cell lines were maintained in DMEM medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Plumbagin was obtained from TCI (Tokyo). Antibodies against RanBP1, Foxo1, p53, p73, p21, and HA tag were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Alexa Fluor 488-conjugated donkey anti-goat antibody and Alexa Fluor 594-conjugated goat anti-mouse antibody were obtained from Invitrogen Life Technology (Invitrogen, Carlsbad, CA, USA).
Nuclear transport functional assays
The inhibition of the CRM1-mediated Foxo1-GFP transport was monitored as follows: HeLa cells were plated in 96-well plates and transfected with plasmids. At 24 h after transfection, test compounds were added to the cells at different concentrations. Inhibition of the CRM1-mediated nucleocytoplasmic transport was measured by verifying the cellular distribution of Foxo1-GFP 2 h after addition of the compounds. Next, cells were fixed for 20 min with 4% formaldehyde in PBS and stained with 10 mg/mL Hoehst 33258 (Sigma-Aldrich). Photomicrographic images were recorded with the use of a confocal laser scanning microscope Fluoview FV10i (Olympus, Tokyo).
Immunofluorescence microscopy
Hela cells were plated on 96-well glass bottom plates. Following the indicated treatments (19) , cells were fixed for 20 min with 4% formaldehyde in PBS. Next, cell membranes were permeabilized by treatment with 0.3% Triton X-100 in PBS for 20 min. After blocking with 1% bovine serum albumin (BSA) in PBS for 1 h, cells were treated with primary antibodies in blocking buffer for 1 h. Anti-mouse Alexa Fluor 594-labeled antibody and anti-rabbit Alexa Fluor 488-labeled antibody were used as secondary antibodies. After washing, cells were stained with 10 mg/mL Hoehst 33258. Photomicrographic images were recorded with the use of a confocal laser scanning microscope Fluoview FV10i (Olympus).
Immunoprecipitation and western blotting
Hela cells were seeded at 60-mm dish and incubated overnight. The cells were treated with 15 mM of plumbagin and incubated for 4 h. Then, cells were lysed in a cold lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and Protease inhibitor cocktail). The supernatant was incubated with anti-CRM1 antibody for 6 h and then with protein A-Sepharose 4B (Amershan Biosciences) for 12 h at 4°C. Immune complexes were washed 3 times with lysis buffer and subjected to western blotting (20) with anti-p21, anti-p53, anti-p73, or anti-Foxo1 antibodies.
Mass spectrometric analysis
Peptide labeling was essentially performed as described in prior studies. A peptide DLLGLCEQK (amino acids sequence 523 -531 of CRM1) and its derivative with Cys 528 replaced by Ser were synthesized (GeneScript, China). One microgram of a peptide was treated with 10 mg of plumbagin in 20 mL of buffer (20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 50% methanol) at 37°C. After 24 h of incubation, an 5-mL aliquot of this solution was mixed with 0.5 mL of the matrix solution (10 mg/mL a-cyano-4-hydroxycinnamic acid in 1:1 acetonitrile:water containing 0.1% TFA). The mixed solution was deposited on a stainless steel sample plate, and the solvent was allowed to evaporate at ambient temperature. This sample was analyzed with a Voyager DE STR MALDI-TOF mass spectrometer (Applied Biosystems, Vernon Hills, IL, USA) in the delayedextraction mode.
Results
Plumbagin inhibits CRM1-dependent nuclear export
RanBP1 is a Ran-binding protein consisting of NES sequences and is a canonical biomarker for CRM1 inhibition (21) . We analyzed the subcellular localization of RanBP1, which is known to be exported from the nucleus to the cytosol in a CRM1-dependent manner. Endogenous RanBP1 is localized to the cytopasm in untreated Hela cells. However, we have found that when the cells are treated with LMB or plumbagin, a clear and rapid shift of RanBP1 from a cytoplasmic localization to nucleus could be observed in a dose-dependent manner (Fig. 1A) . Plumbagin completely blocks RanBP1 nuclear export at 25 mM, with partial inhibition already observable at 20 mM. These results implicate that nuclear protein export was suppressed by plumbagin in a similar fashion to LMB.
We also analyzed the subcellular lacalization of various transfected reporter proteins in the absence or presence of plumbagin. Foxo1, a Forkhead transcription factor, is known to be involved in negatively regulating cell cycle progression and cell survival (22) . Foxo1 is exported from the nucleus to the cytoplasm in a CRM1-dependent manner. In control cells, the transcription factor Foxo1 is localized predominantly in the cytoplasm (Fig. 1B) . In contrast, upon treatment of cells with either 10 nM of LMB or 10 mM of plumbagin for 2 h, the Foxo1-GFP nuclear export is completely blocked. Notably, the antiproliferative activity of plumbagin is consistent with its ability to suppress nuclear export. Plumbagin can induce nuclear accumulation of NES-GFP, which is an artificial reporter protein only containing GFP and an NES sequences (Fig. 1C) . Plumbagin also can inhibit endogenous Foxo1 nuclear export in breast cancer cells (MCF-7) or glioma cells (A172), respectively (Fig. 1D) . These results further implied that CRM1 might be a cellular target of plumbagin.
Plumbagin disrupts the interaction of CRM1 with tumor suppressor proteins
To verify whether plumbagin can direct disrupt CRM1 and tumor suppressor proteins interaction, co-immunoprecipitation assays were performed. Lysates form DMSO control and plumbagin-treated cells were pulleddown with CRM1 antibody and probed with Foxo1, p21, p53, and p73, respectively. In contrast to control cells, few target proteins were precipitated in the treated samples (Fig. 2) . Our results implicate that plumbagin could disrupt the CRM1-Foxo1, CRM1-p21, CRM1-p53, and CRM1-p73 interaction.
Plumbagin targets Cysteine 528 of CRM1
To investigate whether plumbagin could bind covalently to Cys 528 of CRM1 in a similar manner with LMB, we performed a mass spectrometry analysis of a synthetic CRM1 peptide. Analogous to prior studies (23) , both the wild-type peptide containing Cys and the mutant peptide containing Ser at the position corresponding to Cys 528 of CRM1 were synthesized and reacted with plumbagin. Mass spectrometric analysis of the unreacted wild type peptide revealed a mass peak at m/z 1018.5842 (Fig. 3A) . After the incubation with plumbagin, an additional peak at m/z 1206.5746 was detected that corresponds to the covalent adduct of the peptide with plumbagin (Fig. 3B) . However, no peak corresponding to a plumbagin adduct could be observed for the sample derived from the mutant peptide treated with plumbagin (Fig. 3D) . The mass shift between the modified peptide and the parental one was 188, which corresponds to the molecular weight of plumbagin, demonstrating that a Michael addition occurs with polypeptides containing cysteines.
Mutation of CRM1 abolishes the nuclear export inhibition by plumbagin
To further prove that plumbagin regulates tumor suppressor proteins through CRM1 inhibition, we analyzed the subcellular localization of the reporter protein Foxo1-GFP in cells co-expressing either wild-type or C528S mutant CRM1 upon treatment with LMB or plumbagin. As expected, HeLa cells expressing wild type HA-CRM1 or HA-CRM1-C528S both showed a cytoplasmic localization of the reporter protein Foxo1-GFP, demonstrating that exogenous CRM1 does not interfere with nuclear export (Fig. 4A ). Upon addition of LMB or plumbagin to the cells, Foxo1-GFP localization was shifted towards the nucleus in cells expressing wild-type CRM1. However, expression of the HA-CRM1-C528S mutant rendered cells resistant to the treatment of LMB or plumbagin, since Foxo1-GFP localized predominantly to the cytoplasm in these cells. We transiently transfected Hela cells with wild-type or Cys 528 mutant CRM1. The cells expressing HA-CRM1-C528S partially reverse the antiproliferative effects of plumbagin (Fig. 4B) . Thus, based on these experimental observations, we have demonstrated that plumbagin suppressed CRM1 activity, thus affecting tumor suppressor proteins.
Discussion
Plumbagin, a natural compound has been reported to induce apoptosis in several cancer cell lines through affecting several signaling pathways (24) . Yet, the underlying molecular mechanism of the therapeutic effects of plumbagin is still poorly understood. To our knowledge, this is the first report that plumbagin functions as an inhibitor of CRM1-mediated nuclear protein export. The inhibition of nuclear export by plumbagin may account for its therapeutic properties in cancer and inflammatory diseases.
We showed that plumbagin targets Cys 528 of CRM1 similarly to LMB. Mass spectrometric analysis showed that plumbagin could bind directly to a synthetic CRM1-derived peptide containing Cys 528 , but not to a mutated peptide (Cys528Ser) lacking Cys. In addition, the Cys 528 binding is indispensable for both LMB and plumbagin. It is noteworthy that LMB suppresses nuclear export at nanomolar concentration. For plumbagin, by contrast, a higher concentration is required for the inhibitory effects of nuclear export. This is consistent with the much weaker cytotoxicity of plumbagin. This may explain that LMB has significant in vitro potency but is poorly tolerated in vivo (21, 25) . However, with a low toxicity, plumbagin has been routinely used as a traditional herbal drug.
The inhibition of nuclear export by plumbagin may have a profound physiological relevance, particularly for cancer diseases. Mislocalization of a nuclear protein into the cytoplasm can render it ineffective as a tumor suppressor or as a target for chemotherapy. Blocking nuclear export of any or all of these proteins may restore tumor suppression or apoptosis (14) . We showed that plumbagin could disrupt CRM1-Foxo1, CRM1-p21, CRM1-p53, and CRM1-p73 interaction. Our experiments highlighted that nuclear retention of Foxo1 could be observed in the presence of LMB or plumbagin. By contrast, only a cytoplasmic localization of Foxo1 was observed in cells expressing the CRM1-Cys 528 mutant when treated with LMB or plumbagin. This has provided direct evidence that the well-documented antitumor effects of curcumin are truly mediated by CRM1.
Previous studies revealed that the anti-tumor activity of plumbagin is mainly through suppressing constitutive the NF-kB signal pathway. The inhibition of NF-kB activation was accompanied by the inhibition of IkBa degradation. However, the mechanism of blocking IkBa degradation by plumbagin is unclear (3, 4, 9) . IkBa exports from the nucleus in a CRM1-dependent manner. The nuclear retention of IkBa could suppress its degradation, which eventually may lead to blocking the NF-kB pathway (26, 27) . Our results reveal that plumbagin could inhibit degradation of IkBa by abolishing the function of CRM1 in a similar manner as other CRM1 inhibitors.
Overall, our results demonstrated that plumbagin could block CRM1 and thereby modulate nuclear traffic. In particular, we have provided strong evidence supporting that the anti-tumor property of plumbagin is most likely mediated through the suppression of nuclear export. We believe that the future development of low-toxicity, small molecule CRM1 inhibitors may provide a new approach to treating cancer. Our findings provided a good starting point for further studies and may contribute to the development of a new class of CRM1 inhibitors.
